NCT02235961View on ClinicalTrials.gov

Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

163

Participants

Timeline

Start Date

September 4, 2014

Primary Completion Date

July 6, 2016

Study Completion Date

July 6, 2016

Conditions
Metabolism and Nutrition DisorderObesity
Interventions
DRUG

NNC9204-0530

Administered as single subcutaneous (s.c., under the skin) injections.

DRUG

liraglutide

Administered as subcutaneous (s.c., under the skin) injections of 1.8 or 3.0 mg.

DRUG

placebo

Administered as single subcutaneous (s.c., under the skin) injections.

Trial Locations (1)

66212

Novo Nordisk Investigational Site, Overland Park

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT02235961 - Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects | Biotech Hunter | Biotech Hunter